Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by Wide Margin; Guides FY23

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by Wide Margin; Guides FY23

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance

March 1, 2023 4:05 PM EST

Strong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021Positioned for Total Revenue and Net Income Growth in 2023  Xywav Enters 2023 as the Oxybate Therapy of Choice and Company's Largest Product by Net SalesEnhanced Investment in R&D to Advance Pipeline towards Key Value Inflection Points in 2023 and 2024Company is Well-Positioned to Achieve Vision 2025

DUBLIN, March 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the... More